 MacroGenics Inc NASDAQ: MGNX closed the Phase 2 study CP-MGA271-06 of enoblituzumab in the first-line treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck SCCHN. The trial evaluated the regimen of enoblituzumab in combination with. 